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Hyperparathyroid bone disease in chronic
renal failure
T Cundy, N Hamdy, R Gray, B Jackson, J A Kanis
SUMMARY
Much has been learnt over the past 80 years of the pathogenesis and manage-
ment of hyperparathyroid bone disease in uraemia. Clinically it has changed
from a rare disorder of childhood and adolescence to a common and difficult
problem in patients maintained on dialysis programmes. Whereas effective treat-
ments are now availableforhyperparathyroid bonedisease, these arenotcurative
and there is clearly much more work to be done before a full understanding ofits
pathogenesis, and thebest methodsoftreatment andprevention, can bereached.
INTRODUCTION
The skeletal abnormalities found in chronic renal failure are collectively termed
renal osteodystrophy or renal bone disease. These include parathyroid bone
disease, osteomalacia, osteoporosis, osteonecrosis, osteosclerosis and periosteal
new bone formation. The pathogenesis of these disorders has been greatly
clarified since the inception ofregular dialysis programmesfor treatment, with the
result that treatment strategies have become defined more accurately and in
some instances have proved more successful.'-4 This article considers the bone
disease related to increased secretion of parathyroid hormone which gives rise to
parathyroid bone disease or osteitis fibrosa.
Abnormalities in parathyroid function have been known to occur in renal failure
since the turn ofthe century,5 but, in the earlier reported cases, significant clinical
problems were rare, except in children.6'7 It was only with the development of
supportive treatments for renal failure, such as dialysis and transplantation, that
patients survived long enough to develop symptomatic bone disease. This in turn
provided a major stimulus to understand the disorder, even though hyperpara-
thyroid bone disease is not exclusive to renal failure.
THE NATURE OF HYPERPARATHYROID BONE DISEASE
Bone is a self-repairing tissue and normally undergoes a sequence of cellular
events to ensure that skeletal mass and architecture are maintained.8 In the adult
skeleton, this process is termed 'remodelling' and comprises three phases which
occur on the trabecular surfaces of bone. The first is the resorption of a packet of
mineralised bone by the action of bone resorbing cells, the osteoclasts, and takes
one or two weeks to be completed. Following the completion of a resorption
cavity, osteoclasts leave the bone surface and are replaced by osteoblasts which
lay down unmineralised bone matrix (osteoid) in an orderly lamellar array at the
site of previous bone resorption. Some osteoblasts become trapped within the
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osteoid matrix to form osteocytes, and it is thought that these are responsible for
the third phase of bone remodelling which is the mineralisation of this organic
collagen matrix. The remodelling sequence is therefore a phenomenon occurring
at bone surfaces and does not take place at the same rate in all parts of the
skeleton. For example, bone turnover is more rapid in trabecular bone than in
cortical bone where the surface-to-volume ratio is low.
Parathyroid hormone is an important activator of this remodelling sequence. In
the presence of high secretion rates of parathyroid hormone, the frequency of
activation of these remodelling packets is increased.8 The histological conse-
quences are that an increased proportion of the bony surface is involved in both
resorption and formation and lessofthe bonesurface is resting. The rapid rates of
bone resorption are associated with irregular excavations on the bone surface
which can be detected histologically. Local imbalances in formation and resorp-
tion may result in patchy osteopenia, particularly of cortical bone. A further
consequence of rapid rates of bone remodelling is that new bone formed is laid
down in a haphazard fashion rather than in an orderly lamellar array (woven
osteoid). This calcifies gradually to form woven bone occupying a relatively large
volume, and the total bone volume may increase in hyperparathyroid bone
disease so that osteosclerosis and osteoporosis co-exist in the same patient.
These consequences of increased bone turnover impair both the structure and
the mechanical properties ofbone. An additional consequence ofincreased bone
resorption is the deposition of fibrous tissue within the marrow cavity giving rise
to the term 'osteitis fibrosa' for hyperparathyroid bone disease (Fig 1).
Fig. 1. Histological features of parathyroid bone disease in renal failure. Most of the unmineralised
bone surface is occupied by multinucleated osteoclasts resorbing bone. The osteoid surface is
increased due to an increase in the number of bone forming cells. Marrow fibrosis occupies chiefly the
resorption cavity but also extends over the formation surface.
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Fig. 2.
Radiographic features of parathyroid bone
disease in renal failure. Alternate bands of
osteosclerosis give rise to the 'ruggerjersey'
appearance.
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Fig. 4.
X.rays of the wrist toshow marked metaphyseal
erosion due to hyperparathyroidism in an
adolescent (above).
The X ray below shows the response to treat
ment with Ia OHD3.
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Marked sub periosteal erosions of bone in
hyperparathydroism Erosions are more marked on
the radial aspect of the phalanx (left).
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FEATURES OF HYPERPARATHYROID BONE DISEASE
Osteosclerosis isfrequently noted in skeletal radiographs, particularly in the spine
(Fig 2), but the characteristic radiographic feature of hyperparathyroid bone
diseaseis subperiosteal erosionofbone. Erosionsare found mostfrequentlyinthe
radial borders of the phalanges, the distal ends of the clavicles and the terminal
phalanges (Fig 3). Gross erosion of the terminal phalanges (acro-osteolysis) may
result in the collapse ofsoft tissue, normally supported by bone, giving rise to the
appearance ofpseudo-clubbing. In children, erosions are commonly found in the
metaphyseal region of long bones where the rate of bone remodelling is high
(Fig 4). Periosteal new bone formation is a less common feature in renal hyper-
parathyroidism (Fig 5).
Plasma or serum alkaline phosphatase activity is a useful biochemical marker of
bone remodelling, since the bone-derived fraction reflects the numbers of active
osteoblasts. Plasma hydroxyproline, reflecting in part bone collagen destruction
by osteoclasts, may also be used as a biochemical marker, but in renal hyper-
parathyroidism resorption and formation are both increased to a similar extent,
and there is little advantage in measuring both, except for the investigation of
treatment regimes.9
Clinically, hyperparathyroid bone disease may give rise to bone pain, tenderness
and to muscle weakness. Children and adolescents are affected more frequently
and more severely than adults. Metaphyseal erosions in the growing skeleton
seen on x-rays may bear some resemblance to rickets (Fig 6), but may give rise
to marked skeletal deformities (Fig 7). It is for these reasons that almost all the
early descriptions of renal bone disease related to children and adolescents.6 7
Fig. 5. Sub-periosteal new bone formation in hyperparathyroid bone disease. Note the periosteal
elevation along the shafts of the metatarsals.
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Fig. 6. Radiographic features of rickets.
Note the widened epiphyseal plate and
splayed metaphysis which contrasts with
the metaphyseal erosion of hyperpara-
thyroidism (Fig 4).
I LlibaS 1|1 1 1fi~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ .... l~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~'.."'..,
,~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~._.1.. _.....
...... 1.
,l::....>.'......
Fig. 7. Severe metaphyseal bone resorption in the femur
of an adolescent uraemic.
Symptomatic bone disease occurring before end-stage chronic renal failure is
relatively uncommon inadults10 and suggests thepresenceofadditional disorders
interfering with skeletal metabolism, such as nutritional deficiency of vitamin D.
The prevalence of hyperparathyroid bone disease in patients reaching end-stage
chronic renal failure depends on the criteria used for diagnosis. The bones of
most patients show some changes of hyperparathyroidism when examined
microscopically as judged by increased numbers of bone-forming and bone-
resorbing cells, but only 30-40% have significant degrees of osteitis fibrosa.
Less have radiographic changes and a small minority have symptoms. In patients
maintained on haemodialysis treatment the incidence rises, but symptoms are
still confined to a minority in most dialysis centres (10-15 %).10
PATHOGENESIS OF HYPERPARATHYROID BONE DISEASE
There is little doubt that hyperparathyroid bone disease is due to an increased
secretion of parathyroid hormone (PTH) by the parathyroid gland. Eighty years
have now passed since the first description of parathyroid gland enlargement in
uraemia,5 and it has been known for 50 years that this was a common finding.12
However, it is only recently that the causes of increased parathyroid secretion in
uraemia have become clarified.
Abnormalities in phosphate transport appear to be of great importance. The
kidney is a major route for the excretion of phosphate, and when renal function
fails the serum phosphate rises. Albright in the 1930s was the first to speculate
on the importance of phosphate retention in causing hyperparathyroidism in
renal failure by suggesting that hyperphosphataemia might lower serum calcium
values, which would in turn stimulate the parathyroid gland.13 This theory was
later refined by elegant experimental evidence from Slatopolsky and Bricker and
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their colleagues,14 who were able to delay the development of hyperpara-
thyroidism in dogs with progressive renal failure by decremental reductions in
dietary phosphate. In contrast, dogs who were allowed unrestricted dietary
phosphate developed hyperphosphataemia and hyperparathroidism as their
renal function declined.
The discovery that the kidney was the major site of conversion of vitamin D to its
biologically active form, 1 ,25-dihydroxyvitamin D3 (calcitriol),15 provided another
important clue in understanding the pathogenesis of hyperparathyroid bone
disease. Progressive loss of renal tissue and the associated hyperphosphataemia
impair the enzyme responsible for the production of this hormonal form of
vitamin D, in turn responsible for calcium absorption from the gut. Diminished
intestinal absorption of calcium may therefore aggravate hypocalcaemia and, in
turn, increase thesecretionofparathyroid hormoneand the sizeoftheparathyroid
gland.
These hypotheses (Fig 8) have been partially tested in man, but there are still
some gaps in our knowledge. Although these mechanisms are an oversimplific-
ation, they nevertheless provide a useful background on which to investigate
affected patients and to design and test various treatment strategies. Not all
uraemic patients have bone disease, nor will all develop bone disease, despite
the ubiquity of phosphate retention and impaired synthesis of calcitriol. It
becomes relevant, therefore, to pose the question as to why some patients do
not develop bone disease and others are at particular risk. Several factors appear
to predispose to renal bone disease at the time of starting dialysis treatment.
Not surprisingly, these include young age and a long duration of renal
disease. Tubulo-interstitial forms of renal disease more commonly give rise to
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probably this is related
to the destruction of the
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Fig. 8. The role of vitamin D and parathyroid hormone in the pathogenesis of renal bone disease:
Progressive renal disease induces decrements inglomerularfiltration rate(GFR) and synthetic capacity
for calcitriol (1,25(OH)2D3) giving rise to osteomalacia (OM). An increase in plasma phosphate (Pi)
due to the fall in GFR stimulates the secretion of parathyroid hormone (PTH) indirectly by decreasing
plasma calcium levels(Ca). Malabsorptionofcalcium maycontributetosecondary hyperparathroidism.
During progressive renal failure plasma calcium and phosphate tend to remain normal (because ofthe
renal and skeletal effects of PTH) at the expense ofan increasing secretion rate of PTH and its skeletal
consequence, osteitis fibrosa (OF). When the compensatory abilities of the kidney are compromised
by renal failure, hyperphosphataemia and hypocalcaemia prevail. Retention of aluminium may also
cause osteomalacia.
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THERAPEUTIC APPROACHES
Haemodialysis and chronic peritoneal dialysis provide the opportunity for
manipulating the biochemical environment, which can modify bone disease. In
many instances hyperparathyroid bone disease may regress, but sometimes at
the expense of other forms of bone disease. With respect to skeletal metabolism,
the institution of dialysis results in an increase in serum calcium and a decrease in
serum phosphate towards normal values. Adequate control of serum phosphate
may not be achievable by dialysis alone and often requires the use of antacids
such as aluminium hydroxide which bind phosphate in the gut and render it
unavailable for absorption. Despite these dramatic biochemical improvements,
hyperparathyroid bone disease increases both in severity and frequency with
increased duration of dialysis (Fig 9) in most renal units (except those in which
aluminium toxicity is endemic). The normalisation of serum calcium might be
expected to suppress PTH secretion, and in the short term it appears to do so.
Thus, after patients have begun regular haemodialysis, plasma values of alkaline
phosphatase decrease towards normal, and sub-periosteal erosions may heal.
These improvements are, however, transient, and bone disease tends to recur
despite the maintenance of normocalcaemia. A similar approach has been to
increase serum calcium values above normal by the use of high concentrations of
calcium in the dialysis fluid.16 Once again, any improvements which occur in
hyperparathyroid bone disease are transient and are offset by the increased risk
of extraskeletal calcification. In a recent study of long-term survivors on main-
tenance haemodialysis, two-thirds of patients dialysed for 10 or more years
required parathyroidectomy.17
The two mainstays oftreatment ofparathyroid bone disease have been the use of
vitamin D derivatives and parathyroidectomy. The choice of treatment has
chanaed somewhat over the years. Problems with the unDredictable content and
formulation of vitamin D,
vitamin D toxicity and
dangers of increasing extra-
skeletal calcification made
the use of high doses of
vitamin D unpopular. As a
result, in the early 1970s,
the more radical approach
of parathyroidectomy was
favoured.18 The discovery
ofthe renal 1
-hydroxylase
systeml5 and the subse-
quent availability ofcalcitriol
and its synthetic analogues,
1 a-hydroxyvitamin D and
dihydrotachysterol has re-
focussed attention on the
use of preparations of
vitamin D.2,3
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Fig. 9. Natural history of renal bone disease in 207 patients receiving dialysis treatment atthe Oxford
Renal Unit. The prevalence of osteitis fibrosa (with or without osteomalacia) (0) and osteomalacia
alone (El) both increased with time, though changes in the formerare more marked. In the 78 patients
dialysed for 6 years or more, only 13% had no evidence of marked disease (o).
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Vitamin D may act simply by increasing intestinal absorption of calcium and
thereby raising the serum calcium, but some recent research hassuggested that it
may also act directly on parathyroid tissue to suppress its secretion. The evidence
that this contributes to a therapeutic response is not clear. Even less clear is the
question whether or not vitamin D may have a direct action on the skeleton.
Thus, the use of metabolites of vitamin D may improve hyperparathyroid bone
disease by mechanisms in addition to raising serum calcium, but this requires
more investigation.
The short-term responses of many manifestations of hyperparathyroid bone
disease are now well documented in response to treatment with vitamin D
derivatives. Bone pain improves, subperiosteal and metaphyseal erosions heal,
serum alkaline phosphatase and hydroxyproline values fall, and growth in
children may accelerate.19-22 In dialysis-treated patients, the long-term results are
not so reassuring. The histological changes in bone are not as striking as the
clinical, biochemical and radiographic improvements,23 and dialysis-treated
patients appear to respond less favourably than less uraemic patients.24.25
Moreover, following long-term treatment, hyperparathyroidism tends to recur
despite continued treatment and the maintenance of normal or high plasma
calcium levels (Fig 10).26 Although the newer vitamin D compounds are much
easier to control,27 the outcome of therapy with them is comparable to those
observed with high doses of 25-hydroxyvitamin D or vitamin D2.28 29 Never.
theless, the improvement in hyperparathyroid bone disease may persist for many
years and thus vitamin D remains a valuable adjunct to management.
Parathyroidectomy remains an important component of the management of
patients with hyperparathyroid bone disease. Though still a matter for debate,
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Fig. 10. Sequential changes in plasma calcium (mean±SEM), and serum immunoassayable para.
thyroid hormone (iPTH) in 13 patients treated continuously with la .OHD3. Note the sustained
increase in plasma calcium but ill-sustained suppression of iPTH.
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partial parathyroidectomy may be preferable to removal of all parathyroid tissue.
However, the long-term follow-up ofpatients following partial parathyroidectomy
indicates that this treatment, like many others for hyperparathyroid bone disease,
has transient effects, and bone disease tends to recur despite the concurrent use
of vitamin D and the maintenance of normocalcaemia.30 The remission period is
probably longer than that observed in patients treated with vitamin D preparations
alone. One of the reasons for avoiding total parathyroidectomy is that this may
precipitate a refractory form of vitamin D-resistant osteomalacia,31 similar to that
observed in patients with aluminium retention.
A partial or transient suppression of hyperparathyroidism in dialysis-treated
patients therefore seems possible to achieve in a number of ways. These include
phosphate restriction, theinfusionofcalciumvia thedialysate, the useofvitamin D
derivatives or parathyroidectomy. Despite the efficacy of these methods, bone
disease tends to recur, and it is clear that in dialysis patients there remains a
potent stimulus to the growth of parathyroid tissue in addition to low values of
serum calcium. The vigour with which parathyroid tissue continues to grow has
been demonstrated in studies of auto-transplanted parathyroid tissue removed
from patientswith hyperplastic glandsand embedded insternomastoidorforearm
muscles. Such transplanted tissue may become disseminated and histologically
demonstrate paramalignant behaviour by locally invading blood vessels and
muscle tissue.32,33 The nature ofthis stimulus to parathyroid growth is not known.
Research of this aspect of parathyroid function is in its infancy and provides one
of the challenges for the future.
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